1.3201 USD
-0.02 (-1.49%)
We assign a fundamental rating of 4 out of 10 to SBFM. SBFM was compared to 529 industry peers in the Biotechnology industry. While SBFM seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, SBFM is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
SBFM had negative earnings in the past year.
In the past year SBFM has reported a negative cash flow from operations.
SBFM had negative earnings in each of the past 5 years.
SBFM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -19.73%, SBFM is doing good in the industry, outperforming 76.37% of the companies in the same industry.
SBFM's Return On Equity of -24.55% is fine compared to the rest of the industry. SBFM outperforms 79.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.73% | ||
| ROE | -24.55% | ||
| ROIC | N/A |
ROA(3y)-41.58%
ROA(5y)-191.13%
ROE(3y)-55.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SBFM's Gross Margin of 33.33% is fine compared to the rest of the industry. SBFM outperforms 73.16% of its industry peers.
In the last couple of years the Gross Margin of SBFM has declined.
SBFM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 33.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.34%
GM growth 5Y-8.47%
2. Health
2.1 Basic Checks
SBFM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SBFM has more shares outstanding
Compared to 5 years ago, SBFM has more shares outstanding
There is no outstanding debt for SBFM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
SBFM has an Altman-Z score of -1.11. This is a bad value and indicates that SBFM is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.11, SBFM is in line with its industry, outperforming 54.06% of the companies in the same industry.
SBFM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.11 |
ROIC/WACCN/A
WACC8.83%
2.3 Liquidity
A Current Ratio of 5.00 indicates that SBFM has no problem at all paying its short term obligations.
The Current ratio of SBFM (5.00) is comparable to the rest of the industry.
A Quick Ratio of 2.66 indicates that SBFM has no problem at all paying its short term obligations.
With a Quick ratio value of 2.66, SBFM is not doing good in the industry: 68.05% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5 | ||
| Quick Ratio | 2.66 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 60.54% over the past year.
The Revenue has grown by 44.75% in the past year. This is a very strong growth!
SBFM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 340.61% yearly.
EPS 1Y (TTM)60.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.79%
Revenue 1Y (TTM)44.75%
Revenue growth 3Y434.8%
Revenue growth 5Y340.61%
Sales Q2Q%11.64%
3.2 Future
The Earnings Per Share is expected to grow by 41.20% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 15.04% on average over the next years. This is quite good.
EPS Next Y98.01%
EPS Next 2Y41.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-0.21%
Revenue Next 2Y15.04%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SBFM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SBFM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SBFM's earnings are expected to grow with 41.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.2%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for SBFM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:SBFM (12/15/2025, 11:44:24 AM)
1.3201
-0.02 (-1.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners7.51%
Inst Owner Change25.57%
Ins Owners0%
Ins Owner Change0%
Market Cap6.48M
Revenue(TTM)34.87M
Net Income(TTM)-6.31M
Analysts82.86
Price Target6.12 (363.6%)
Short Float %12.03%
Short Ratio0.62
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.29%
PT rev (3m)-14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-44.44%
EPS NY rev (1m)-21.69%
EPS NY rev (3m)-77.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.26%
Revenue NY rev (1m)-8.96%
Revenue NY rev (3m)-16.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.18 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.25 | ||
| P/tB | 0.28 | ||
| EV/EBITDA | N/A |
EPS(TTM)-51.88
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-1.88
FCFYN/A
OCF(TTM)-1.58
OCFYN/A
SpS7.4
BVpS5.23
TBVpS4.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.73% | ||
| ROE | -24.55% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 33.33% | ||
| FCFM | N/A |
ROA(3y)-41.58%
ROA(5y)-191.13%
ROE(3y)-55.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.34%
GM growth 5Y-8.47%
F-Score4
Asset Turnover1.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 549.76% | ||
| Cap/Sales | 4.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5 | ||
| Quick Ratio | 2.66 | ||
| Altman-Z | -1.11 |
F-Score4
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)874.71%
Cap/Depr(5y)526.53%
Cap/Sales(3y)5.32%
Cap/Sales(5y)3.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.79%
EPS Next Y98.01%
EPS Next 2Y41.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)44.75%
Revenue growth 3Y434.8%
Revenue growth 5Y340.61%
Sales Q2Q%11.64%
Revenue Next Year-0.21%
Revenue Next 2Y15.04%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y5.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.81%
OCF growth 3YN/A
OCF growth 5YN/A
SUNSHINE BIOPHARMA INC / SBFM FAQ
Can you provide the ChartMill fundamental rating for SUNSHINE BIOPHARMA INC?
ChartMill assigns a fundamental rating of 4 / 10 to SBFM.
What is the valuation status for SBFM stock?
ChartMill assigns a valuation rating of 1 / 10 to SUNSHINE BIOPHARMA INC (SBFM). This can be considered as Overvalued.
How profitable is SUNSHINE BIOPHARMA INC (SBFM) stock?
SUNSHINE BIOPHARMA INC (SBFM) has a profitability rating of 2 / 10.
What is the financial health of SUNSHINE BIOPHARMA INC (SBFM) stock?
The financial health rating of SUNSHINE BIOPHARMA INC (SBFM) is 6 / 10.
Can you provide the expected EPS growth for SBFM stock?
The Earnings per Share (EPS) of SUNSHINE BIOPHARMA INC (SBFM) is expected to grow by 98.01% in the next year.